Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Decline in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totalling 94,000 shares, a decline of 17.5% from the November 30th total of 114,000 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily volume of 90,000 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analyst Weigh In

Several research firms have commented on PSTV. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research note on Tuesday, November 26th. Ascendiant Capital Markets lowered their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Price Performance

Shares of Plus Therapeutics stock traded down $0.01 during trading on Monday, hitting $1.15. The stock had a trading volume of 43,799 shares, compared to its average volume of 63,767. The business has a fifty day moving average of $1.26 and a two-hundred day moving average of $1.46. The firm has a market cap of $6.78 million, a P/E ratio of -0.45 and a beta of 0.70. Plus Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $2.67.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.